NewAmsterdam Pharma logo

NewAmsterdam Pharma

NAMS | NASDAQ
Chart Builder DCF Calculator
$19.46
-$0.68 (-3.38%)
At close: Nov 16, 2026, 4:00 PM ET
$19.46
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.38%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
43.9
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #423/1021 (Top 41%)

Key Statistics

Market Data

Market Cap $2.33B
1D Range
19.45 20.54
52W Range
18.89 41.45

Valuation (TTM)

PE -11.38
PB 3.70
EV/EBITDA -8.35

Valuation (NTM)

Forward PE N/A
Forward PEG 78.41
Price Target $54.50
Loading financial charts...

Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral ...

Sector Healthcare
Industry Biotechnology
Employees 100
IPO Date Feb 9, 2021
Fiscal Year January - December

Latest News

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates

13 days ago · zacks.com

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

13 days ago · globenewswire.com

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November

14 days ago · globenewswire.com

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease

2 months ago · globenewswire.com

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®

2 months ago · prnewswire.com

Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®

2 months ago · globenewswire.com

NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago · globenewswire.com

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

3 months ago · globenewswire.com

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

3 months ago · globenewswire.com

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

3 months ago · marketbeat.com

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$0.14
Beat +70.33%
REV
$19.16M
Beat +117.28%
Next Earnings
Feb 17, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$54.50
Upside
+180.06%
Buy (6)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.